TG Therapeutics’ (TGTX) “Buy” Rating Reaffirmed at Ladenburg Thalmann
Ladenburg Thalmann reissued their buy rating on shares of TG Therapeutics Inc. (NASDAQ:TGTX) in a report released on Saturday. The brokerage currently has a $28.00 price target on the biopharmaceutical company’s stock.
Other equities analysts have also issued reports about the company. S&P Equity Research cut their price objective on TG Therapeutics from $7.15 to $6.40 in a research note on Wednesday, August 24th. Roth Capital reaffirmed a buy rating and issued a $33.00 price objective on shares of TG Therapeutics in a research note on Friday. Brean Capital reiterated a buy rating and issued a $28.00 target price on shares of TG Therapeutics in a report on Thursday, October 6th. FBR & Co reiterated a buy rating on shares of TG Therapeutics in a report on Monday, September 19th. Finally, Zacks Investment Research downgraded TG Therapeutics from a strong-buy rating to a hold rating in a report on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. TG Therapeutics presently has an average rating of Buy and an average target price of $21.21.
TG Therapeutics (NASDAQ:TGTX) traded down 3.80% during midday trading on Friday, hitting $6.59. The stock had a trading volume of 1,109,795 shares. TG Therapeutics has a 1-year low of $5.41 and a 1-year high of $14.87. The stock’s 50-day moving average is $7.39 and its 200-day moving average is $7.37. The stock’s market capitalization is $358.87 million.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. On average, equities research analysts anticipate that TG Therapeutics will post ($1.22) EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. BlackRock Advisors LLC increased its stake in TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares in the last quarter. Mariner Wealth Advisors LLC increased its stake in TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 800 shares in the last quarter. SECOR Capital Advisors LP purchased a new stake in TG Therapeutics during the second quarter valued at approximately $187,000. Emerald Acquisition Ltd. purchased a new stake in TG Therapeutics during the second quarter valued at approximately $190,000. Finally, Rhumbline Advisers increased its stake in TG Therapeutics by 9.0% in the second quarter. Rhumbline Advisers now owns 37,547 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 3,107 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.